

Message Text

UNCLASSIFIED

PAGE 01 TOKYO 10281 080818Z

12

ACTION OES-06

INFO OCT-01 EA-09 ISO-00 HEW-06 /022 W

----- 052122

R 080811Z JUL 76

FM AMEMBASSY TOKYO

TO SECSTATE WASHDC 0654

UNCLAS TOKYO 10281

DEPT PASS TO FDA AND NIH

E.O. 11652: N/A

TAGS: TBIO, JA

SUBJECT: ARTIFICIAL BLOOD

1. MIDORI JUJI CO., LTD., A PHARMACEUTICAL FIRM IN OSAKA, ANNOUNCED JULY 6 THAT IT HAS SUCCEEDED IN DEVELOPING "OXYGEN INFUSION FLUID" (FLUOROCARBON EMULSION), A SUBSTITUTE FOR BLOOD, AND HAS STARTED MANUFACTURE AND SALE OF "FC-43" TO BE USED IN EXPERIMENTAL ANIMALS FOR RESEARCH PURPOSES.

2. FIRM WILL EXPORT FC-43 TO THE US UNDER EXPORT CONTRACT CONCLUDED WITH GRAND ISLAND BIOLOGICAL CO., AMERICAN MANUFACTURER OF BIOMEDICAL REAGENTS.

3. IN 1971, MIDORI JUJI SIGNED CONTRACT WITH TANABE PHARMACEUTICAL COMPANY IN JAPAN, CUTTER CO. IN THE US, AND VIRTUM IN SWEDEN FOR RESEARCH AND DEVELOPMENT ON ARTIFICIAL BLOOD. FACULTY OF MEDICINE OF KOBE UNIVERSITY HAS COOPERATED IN RESEARCH AND DEVELOPMENT (TANABE HAS RECENTLY WITHDRAWN FROM CONTRACT). CONTRACT ON R&D COLLABORATION CALLS FOR JOINT RESEARCH AND DEVELOPMENT, SHARING OF RESEARCH PROGRAMS AND MUTUALLY EXCHANGING RESEARCH RESULTS, JOINT OWNERSHIP OF PATENT RIGHTS, AND CONCERTED SALES ACTIVITIES. AS FAR AS FC-43 IS CONCERNED, MIDORI JUJI WILL INDEPENDENTLY MARKET THE PRODUCT.

4. NEXT SPRING, MIDORI JUJI PLANS TO COMMERCIALIZE ARTIFICIAL BLOOD TO BE USED IN HUMANS. PRODUCT TO BE PLACED

UNCLASSIFIED

PAGE 02 TOKYO 10281 080818Z

ON MARKET FIRST WILL BE FOR PERFUSION OF BLOOD VESSELS OF

TRANSPLANTED KIDNEYS (SUPPLYING OXYGEN WHILE CLEANSING
BLOOD VESSELS OF THE KIDNEY).
HODGSON

UNCLASSIFIED

NNN

Message Attributes

Automatic Decaptioning: X
Capture Date: 01 JAN 1994
Channel Indicators: n/a
Current Classification: UNCLASSIFIED
Concepts: BLOOD, MEDICAL RESEARCH
Control Number: n/a
Copy: SINGLE
Draft Date: 08 JUL 1976
Decaption Date: 01 JAN 1960
Decaption Note:
Disposition Action: n/a
Disposition Approved on Date:
Disposition Authority: n/a
Disposition Case Number: n/a
Disposition Comment:
Disposition Date: 01 JAN 1960
Disposition Event:
Disposition History: n/a
Disposition Reason:
Disposition Remarks:
Document Number: 1976TOKYO10281
Document Source: CORE
Document Unique ID: 00
Drafter: n/a
Enclosure: n/a
Executive Order: N/A
Errors: N/A
Film Number: D760263-0065
From: TOKYO
Handling Restrictions: n/a
Image Path:
ISecure: 1
Legacy Key: link1976/newtext/t19760777/aaaacpth.tel
Line Count: 64
Locator: TEXT ON-LINE, ON MICROFILM
Office: ACTION OES
Original Classification: UNCLASSIFIED
Original Handling Restrictions: n/a
Original Previous Classification: n/a
Original Previous Handling Restrictions: n/a
Page Count: 2
Previous Channel Indicators: n/a
Previous Classification: n/a
Previous Handling Restrictions: n/a
Reference: n/a
Review Action: RELEASED, APPROVED
Review Authority: schwenja
Review Comment: n/a
Review Content Flags:
Review Date: 26 MAY 2004
Review Event:
Review Exemptions: n/a
Review History: RELEASED <26 MAY 2004 by chengls>; APPROVED <11 AUG 2004 by schwenja>
Review Markings:

Margaret P. Grafeld
Declassified/Released
US Department of State
EO Systematic Review
04 MAY 2006

Review Media Identifier:
Review Referrals: n/a
Review Release Date: n/a
Review Release Event: n/a
Review Transfer Date:
Review Withdrawn Fields: n/a
Secure: OPEN
Status: NATIVE
Subject: ARTIFICIAL BLOOD
TAGS: TBIO, JA, MIDORI JUJI CO
To: STATE
Type: TE
Markings: Margaret P. Grafeld Declassified/Released US Department of State EO Systematic Review 04 MAY 2006